Whether inhibition of IDO1 alone is sufficient to overcome pathway dysregulation is uncertain, as exemplified by the recent negative results seen with epacadostat in patients with melanoma.14 Indeed, a planned Phase 3 trial of this agent in combination with pembrolizumab in patients with RCC has been halted based on these findings. Here, IDO1 is linked to renal cell carcinoma.